GW&K Investment Management LLC trimmed its position in Alkermes Plc (NASDAQ:ALKS) by 0.6% in the fourth quarter, HoldingsChannel reports. The firm owned 306,678 shares of the company’s stock after selling 1,853 shares during the quarter. GW&K Investment Management LLC’s holdings in Alkermes were worth $16,784,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in Alkermes by 13.7% in the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock worth $134,726,000 after purchasing an additional 319,014 shares in the last quarter. Northern Trust Corp grew its stake in Alkermes by 0.9% in the second quarter. Northern Trust Corp now owns 854,816 shares of the company’s stock worth $49,554,000 after purchasing an additional 7,845 shares in the last quarter. AMP Capital Investors Ltd grew its stake in Alkermes by 11.0% in the third quarter. AMP Capital Investors Ltd now owns 53,745 shares of the company’s stock worth $2,732,000 after purchasing an additional 5,306 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in Alkermes in the third quarter worth about $284,000. Finally, Los Angeles Capital Management & Equity Research Inc. grew its stake in Alkermes by 206.3% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 261,977 shares of the company’s stock worth $13,319,000 after purchasing an additional 176,442 shares in the last quarter. Institutional investors and hedge funds own 99.20% of the company’s stock.

In other news, insider Shane Cooke sold 6,207 shares of Alkermes stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $60.22, for a total transaction of $373,785.54. Following the sale, the insider now owns 80,915 shares of the company’s stock, valued at $4,872,701.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard F. Pops sold 50,000 shares of Alkermes stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 142,624 shares of company stock worth $7,633,176. Corporate insiders own 5.34% of the company’s stock.

A number of equities analysts recently commented on ALKS shares. Barclays downgraded Alkermes from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $66.00 to $50.00 in a research note on Monday, October 16th. Mizuho set a $81.00 price target on Alkermes and gave the stock a “buy” rating in a research note on Saturday, October 21st. ValuEngine downgraded Alkermes from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Citigroup set a $62.00 target price on Alkermes and gave the company a “hold” rating in a research note on Thursday, October 26th. Finally, Credit Suisse Group decreased their target price on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Alkermes has a consensus rating of “Hold” and an average target price of $63.33.

Alkermes Plc (NASDAQ ALKS) opened at $57.03 on Monday. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes Plc has a 52 week low of $46.42 and a 52 week high of $63.40. The company has a market capitalization of $8,769.84, a P/E ratio of -51.38 and a beta of 2.13.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same period in the previous year, the firm posted ($0.09) earnings per share. Alkermes’s quarterly revenue was up 20.6% compared to the same quarter last year. equities research analysts predict that Alkermes Plc will post -0.59 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/01/22/gwk-investment-management-llc-decreases-position-in-alkermes-plc-alks.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.